Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Maldonado

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
International Journal of Radiation Oncology, Biology, Physics|September 7, 2016
Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 TrialAlmudena Zapatero, Araceli Guerrero, Xavier Maldonado, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 8, 2021
Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trialAlmudena Zapatero, Ana Álvarez, Araceli Guerrero, et al.
Lancet (London, England)|November 23, 2024
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial designAlberto Bossi, Stéphanie Foulon, Xavier Maldonado, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2025
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trialAdrien Rousseau, Maryam Karimi, Stefan Michiels, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 27, 2022
Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensusMarta Bonet, David González, José-Enrique Baquedano, et al.
The Lancet. Oncology|February 24, 2015
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trialAlmudena Zapatero, Araceli Guerrero, Xavier Maldonado, et al.
The Lancet. Oncology|April 15, 2022
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trialAlmudena Zapatero, Araceli Guerrero, Xavier Maldonado, et al.
International Journal of Radiation Oncology, Biology, Physics|October 16, 2018
Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer PatientsJoan Carles, Enrique Gallardo, Montserrat Doménech, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2025
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trialGuilhem Roubaud, Marie Kostine, Raymond S McDermott, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 15, 2010
Treatment of localised prostate cancer with radiation therapy: evidence versus opinionFerran Guedea, Alfredo Ramos, Ismael Herruzo, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
International Journal of Radiation Oncology, Biology, Physics|September 7, 2016
Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 TrialAlmudena Zapatero, Araceli Guerrero, Xavier Maldonado, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 8, 2021
Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trialAlmudena Zapatero, Ana Álvarez, Araceli Guerrero, et al.
Lancet (London, England)|November 23, 2024
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial designAlberto Bossi, Stéphanie Foulon, Xavier Maldonado, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2025
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trialAdrien Rousseau, Maryam Karimi, Stefan Michiels, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 27, 2022
Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensusMarta Bonet, David González, José-Enrique Baquedano, et al.
The Lancet. Oncology|February 24, 2015
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trialAlmudena Zapatero, Araceli Guerrero, Xavier Maldonado, et al.
The Lancet. Oncology|April 15, 2022
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trialAlmudena Zapatero, Araceli Guerrero, Xavier Maldonado, et al.
International Journal of Radiation Oncology, Biology, Physics|October 16, 2018
Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer PatientsJoan Carles, Enrique Gallardo, Montserrat Doménech, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2025
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trialGuilhem Roubaud, Marie Kostine, Raymond S McDermott, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 15, 2010
Treatment of localised prostate cancer with radiation therapy: evidence versus opinionFerran Guedea, Alfredo Ramos, Ismael Herruzo, et al.
Pageof 5